Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report.
BACKGROUND
Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation.


METHODS
We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease.


CONCLUSIONS
Immune checkpoint inhibitors may be active in neuroendocrine cervical cancer, with potential for dramatic responses in a modest subset of patients.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Irvine Medical Center, 33 City Blvd. West #1400, Orange, CA 92868 USA.
Sarah E
SE
Paraghamian
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Irvine Medical Center, 33 City Blvd. West #1400, Orange, CA 92868 USA.
Teresa C
TC
Longoria
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Irvine Medical Center, 33 City Blvd. West #1400, Orange, CA 92868 USA.
Ramez N
RN
Eskander
Cervical cancer; Immunotherapy; Nivolumab; PD-1 inhibitor; Small cell neuroendocrine carcinoma